spacer
home > ebr > Summer 2018
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2018

   
Text
PDF
Editor’s Letter

EBR Editor Dr Deborah O’Neil details the history of diabetes treatments and how they have changed over the last eight decades, while also summarising the themes covered by the issue’s authors.
 
view
download pdf
Science and Innovation
In Brief

Natural Intelligence Looks at AI

EBR's Industry Advisor, Emile Bellott, assesses how the biopharmaceutical industry and human health can benefit from the use of artificial intelligence.
 
view
download pdf
bullet
PATENTING POLICY AND PRACTICE
Considerations for Protecting and Launching Biosimilars

Patenting Biosimilars

A streamlined process is enabling generics companies to enter the market with a biosimilar product and gain approval quicker than ever before, as explained by Jennifer O’Farrell at Boult Wade Tennant.
 
view
download pdf
Biosimilar Applications

The Patent Dance

Sanya Sukduang and Thomas J Sullivan at Finnegan detail how biosimilar applicants can now bypass the usual lengthy information exchange after the introduction of new biologics licensing rules.
 
view
download pdf
bullet
Mass Spectrometry
Primary Sequence Analysis

Understanding Biosimilars

Amino acid sequencing relies on state-of-the-art technology to deliver the best possible analytics, though the mass spectrometry involved can be problematic, as discussed by Dr Richard Easton and Dr Andrew Reason at BioPharmaSpec.
 
view
download pdf
Monitoring with Mass Spectrometry

Driving Discovery

EBR asked Dr Simon Cubbon at Thermo Fisher Scientific about the benefits of using a mass spectrometry-based multi-attribute method in drug development.
 
view
download pdf
Probing Pathology with MALDI

Visualising Alzheimer’s

Dr Shannon Cornett at Bruker Daltonics suggests the ways in which ultra-high resolution mass
spectrometry imaging techniques can be advantageous in understanding neurological disorders.
 
view
download pdf
bullet
Orphan Drugs
Gene Therapy

End of the Tunnel

Dr Serge Braun at AFM-Téléthon examines the ever-changing climate of gene therapy technologies and how they are applied and outlines the limitations that they may present.
 
view
download pdf
bullet
Analytical Tools
Monoclonal Antibody Innovations

Enhancing Analysis

A growing need for rapid high-throughput analysis of biotherapeutics results in the necessity of standardised chromatographic methods, as told by Dr Amy Farell,Dr Sara Carillo, and Dr Jonathan Bones at the National Institute of Bioprocessing Research and Training.
 
view
download pdf
bullet
Genomics and DNA
Red Biotechnology

Endonuclease Compliance

New enzyme derivatives are being welcomed across the biopharmaceuticals industry following easier red biotechnology applications, as illustrated by Dr Pablo Domínguez de María on behalf of c-LEcta and Dr Stefan Schoenert at c-LEcta.
 
view
download pdf
RPA Development

Technique Transition

Dr Olaf Piepenburg at TwistDx explores the advantages of recombinase polymerase amplification, which is growing in popularity as an alternative to traditional polymerase chain reactions for testing outside the laboratory.
 
view
download pdf
Tumour Heterogeneity

Alternative Approaches

Dr Ute Boronowsky at Oxford Genetics introduces a new gene editing tool that has been developed to iron out issues often encountered during single-cell analysis.
 
view
download pdf
bullet
Biosimilars
Diabetes Biosimilars

Calibrating Expectations

Rafal Kokolus, Dr Doug Niven, and Rohit Sood at Syneos Health claim that diabetes treatments could change following the increasing incorporation of biosimilars as an alternative therapeutic.
 
view
download pdf
bullet
ADCs as Therapeutics
ADC Development

Targeted Treatment

Given the rise in usage of antibody-drug conjugates in cancer therapy, addressing the problems they sometimes present is important. Edward Barnes, Dr David Bunka, and Dr Arron Tolley at Aptamer Group demonstrate how aptamers can help alleviate these.


 
view
download pdf
Advancing ADC Technology

The Future of ADCs

Changed approaches and new technologies in the drugs’ development sector has given rise to improved and innovative targeted drugs, as explained byDr Neil Butt at IONTAS.
 
view
download pdf
Targeted Therapies

Engineering Antibodies

Targeted antibodies are always evolving, though the challenges they often come with still remain. Professor Andreas Pahl at Heidelberg Pharma illustrates the ways in which these can be overcome.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement